This is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase 2 study to evaluate the efficacy and safety of UI030 in COVID-19 patients

Patients with moderate and severe COVID-19 were randomly assigned (1:1) to receive either UI030 (Budesonide/Arformoterol dry powder inhaler, 2 inhalations b.i.d) or placebo for 2 weeks.

Inclusion Criteria:

• Adult, aged 19 years or above
• New onset of symptoms suggestive of COVID-19 (fever, cough, soar throat, etc) or diagnosed with COVID-19 within 7 days of participant being seen at visit 1
• In the Investigator's opinion, is able and willing to comply with all trial requirements

Exclusion Criteria:

• A condition requiring invasive oxygen support;
• History of hypersensitivity to budesonide and arformoterol
• Pregnancy, Breast-feeding
• Participation in other clinical studies within 4 weeks prior to enrollment in this study.
• Refusal of the patient to continue participating in the study/withdrawal of informed consent by the patient.